Face Time

| FROM THE PRINT EDITION |
 
 

Martin Siegel, MD Swedish Polyclinic

Martin Siegel has more than his fair share of accolades and accomplishments. The former director of epidemiology at Swedish Health Services and member of the board of trustees at Swedish, he won Case Western Reserve University’s Alfred S. Maschke Award for Clinical Excellence, and is frequently selected as one of Seattle’s top doctors. But in the end, the real meaning in his professional life comes from the face-to-face time he spends with patients.

When he meets with patients, who are often at their most vulnerable, he always introduces himself as Marty Siegel, not Dr. Siegel, and encourages questions.

“If patients can be engaged in their care, asking questions, that’s a good sign,” he says. “It breaks down some of the misconceptions of what the experience will be like by having them ask questions.”

And while the art of health care has morphed over the past three decades into something more austere and business oriented, Siegel, who is an infectious disease specialist at The Polyclinic, remains steadfast in his commitment to patients.

“What I treasure most is my experience at the bedside, talking to families and working with patients,” Siegel says. “The greatest pleasure is seeing people get better.”

When he began practicing in 1983, patient care was always his top priority. But by 1986, the health care environment was akin to practicing “alone together”; doctors weren’t communicating with one another. However, in the last 10 years at The Polyclinic, there has been a much greater recognition of the interdependence of doctors in providing the best care for their patients. Personalized care is written into the clinic’s mission statement. That approach has been a blessing for Siegel and the group of physicians he works with in Seattle.

“The emphasis on quality [of care] over the past decade has really helped create alignment among various caregivers in the community,” Siegel says. “It’s led to tremendous motivation on everyone’s part to do a better job for the patients.”

Siegel continues to proselytize the importance of personalized care with residents. A clinical professor of medicine at the UW’s School of Medicine, he has won the resident teaching award twice at Swedish Medical Center and once at Providence Medical Center—the only physician to win the prestigious award at both institutions.

RUNNERS-UP>>>

Patricia Dawson, Medical director, Swedish Medical Center

Since beginning her medical career in the 1970s, Patricia Dawson has made significant strides as a caregiver. As the medical director and a breast surgeon at the Comprehensive Breast Center at the Swedish/Cherry Hill Campus, Dawson focuses on building relationships with her patients. In 2012, she will head up her most ambitious project yet, the True Family Women’s Cancer Center. Addressing the physical, psychosocial and educational needs of women with cancer, the center will be the Northwest’s largest and most comprehensive unit devoted to treating cancers affecting women.

Stephen Setter, Associate professor of pharmacotherapy, Washington State University

A popular professor with pioneering pharmacy practice Elder Services, Stephen Setter’s contributions to the field of pharmacy reach beyond the arenas of patient care and education. He is an active researcher in the pharmaceutical care of older adults, with notable work in the early detection and resolution of medication discrepancies in home-bound elderly patients, for which WSU received funding from the prestigious Robert Wood Johnson Foundation. He was one of the founding board members of the Parkinson’s Resource Center of Spokane and often gives free medication consultations to people with Parkinson’s disease.

Inspired Innovation at Fred Hutch

Inspired Innovation at Fred Hutch

Using the natural defenses of plants and animals, Dr. Jim Olson and his team engineer proteins to attack the most treatment-resistant malignancies.
| FROM THE PRINT EDITION |
 
 

On the fifth floor of the Fred Hutchinson Cancer Research Center in Seattle, Dr. Jim Olson and his team are training a robot to process and purify hardy peptides known as knottins, some of which are natural compounds made by plants and animals as diverse as sunflowers and scorpions.

The robot will be capable of churning out work at 50 times the speed of Olson’s best scientists. Olson, a neuro-oncologist at Seattle Children’s Hospital, walks fast, talks fast and carries a big ambition because of the young cancer patients he has known. He once lost an 11-year-old patient named Violet to brain cancer. That experience inspired him to create Project Violet, which raises money for his laboratory’s work at Fred Hutch.

Olson believes knottins can be engineered into therapies that may help thousands of patients to avoid Violet’s fate. He aims to use them not just for brain cancer, but also for Alzheimer’s and other neurodegenerative diseases and maybe even arthritis.  

The reason he sees such a big therapeutic landscape for these compounds has to do with their folded and knotted shape — hence the coinage “knottins.” Their knotted shapes allow them to go places in the human body where other drug therapies can’t easily reach. Olson proudly wears on his upper arm a simplified tattoo shaped liked one of his favorite knottins.

Olson is probably best-known for having invented Tumor Paint, a product that uses the capability of scorpion venom to cross the blood-brain barrier and bind to cancerous tissue. As noted in the September 2012 issue of Seattle Business, he hitched that protein to what he calls a molecular flashlight, a dye that fluoresces when exposed to near-infrared light. 

The clinical version of this paint, BLZ-100 Tumor Paint, won designation from the Food and Drug Administration in 2014 for use on brain tumors. When injected into a patient, the engineered molecule travels to the tumor and makes it glow so surgeons can see its precise boundaries. BLZ-100 is slowly working its way through clinical trials and is being developed by Blaze Bioscience, a private company cofounded by Olson. Recently, Blaze published in the medical journal JAMA a report about research on mice that shows BLZ-100 may eventually be helpful for treating head and neck cancers. 

While working on Tumor Paint, Olson became convinced his team could engineer other knottins for human therapies. Different knottins travel to different parts of the body. Some can cross the blood-brain barrier, making them potentially useful for delivering drugs to the brain, but others have distinct characteristics that allow them to avoid being destroyed by stomach acid and human enzymes. One he has studied in mice travels to the joints, and he imagines hitching a pain reliever to it as an improvement on oral medications for arthritis.

Pharmaceutical companies have known about knottins for years. For a variety of reasons — including the inability to grow them easily in yeast or bacteria, the typical laboratory workhorses — they have been unable to tap their power. Olson discovered he could replicate the proteins by “growing” them inside human kidney cells, a crucial breakthrough. Olson’s team changes the proteins, in some cases giving them payloads to kill cancer cells. Once engineered, they are called optides — an optimized peptide.

Olson’s lab at Fred Hutch has a staff of about 30. He declined to say specifically how much money it spends in a year but described it as similar to a biotech company that might spend $5 million in a year’s time. It occupies about 40,000 square feet. 

The laboratory robot, which cost about $750,000, was custom designed to enable Olson’s lab to generate, process and purify more knottins. An expert scientist might be able to process 10 molecules per week. The robot can produce 500 in the same time.

The idea for the robot came as Olson was talking about his work with a software executive. “He asked me: ‘What is your pain point?’” Olson remembers. Olson, who loves borrowing strategies from software engineering or the tech sciences and applying them to medical research, says automating the process of growing and purifying new compounds struck him as a “pain point” he could target.

That “aha” moment occurred two years ago; the robot arrived earlier this year. By the end of the year, the lab hopes to have a library of 10,000 optides, which will give scientists a far better chance of finding one likely to attach itself to a target of interest, such as a particular lung cancer cell.

Department of Arts and Sciences

Jim Olson likes his team to draw inspiration from art and music. He invited his team to try glassblowing at the Museum of Glass in Tacoma, and their product — some lavender teardrop shapes — hang in the laboratory window in honor of Project Violet.

Two years ago, Olson decided to produce a folk-pop CD — The Violet Sessions — featuring local artists Hey Marseilles, Noah Gundersen, Ben Fisher, Le Wrens, OK Sweetheart, Naomi Wachira and St. Paul De Vence. The crowdfunded project helped raise more than $10,000 for the Olson lab’s research. The CD is still available online and the music can be downloaded via iTunes.

“Creativity is dulled by meetings and piqued by novel experiences,” Olson observes. This appreciation of creativity has been particularly helpful in generating fundraising ideas that are crucial to the success of his laboratory. For example, lab employees came up with the idea of carnival games to help attendees at a recent fundraiser understand the fundamental science taking place. They created an optide bean bag toss with bags of different sizes representing a range of drug candidates. These “drug candidates” had to be tossed into containers of varying sizes that represented the drug targets, such as assorted cancer cells. The event raised more than $500,000.